Adherence to PCSK9 Inhibitors in Clinical Practice
Top Cited Papers
Open Access
- 17 April 2026
- journal article
- Published by Elsevier in JACC: Advances
- Vol. 5 (5) , 102733
Abstract
No abstract availableKeywords
Funding Information
- University of Hong Kong
- U.S. Food and Drug Administration
This publication has 117 references indexed in Scilit:
- Persistence and Adherence to PCSK9 Inhibitor Monoclonal Antibodies Versus Ezetimibe in Real-World SettingsAdvances in Therapy, 2024
- Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in GermanyClinical Research in Cardiology, 2023
- Patient adherence to fully reimbursed proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) treatmentWiener klinische Wochenschrift, 2023
- Meta‐analysis of prevalence: I2 statistic and how to deal with heterogeneityResearch Synthesis Methods, 2022
- Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational StudyAdvances in Therapy, 2021
- Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the USJAMA Cardiology, 2021
- Poor adherence and persistence to sodium glucose co‐transporter 2 inhibitors in real‐world settings: Evidence from a systematic review and meta‐analysisDiabetes/Metabolism Research and Reviews, 2020
- Adverse Events Associated With PCSK9 Inhibitors: A Real‐World ExperienceClinical Pharmacology & Therapeutics, 2018
- PCSK9 inhibitor access barriers—issues and recommendations: Improving the access process for patients, clinicians and payersClinical Cardiology, 2017
- Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular DiseaseJAMA, 2016